JP2024545184A - メニン－ｍｌｌ相互作用の阻害剤 - Google Patents

メニン－ｍｌｌ相互作用の阻害剤 Download PDF

Info

Publication number
JP2024545184A
JP2024545184A JP2024534648A JP2024534648A JP2024545184A JP 2024545184 A JP2024545184 A JP 2024545184A JP 2024534648 A JP2024534648 A JP 2024534648A JP 2024534648 A JP2024534648 A JP 2024534648A JP 2024545184 A JP2024545184 A JP 2024545184A
Authority
JP
Japan
Prior art keywords
compound
pharma
formula
solvate
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545184A5 (https=
Inventor
アバギャン，ルーベン
ゼノノヴィチ パーチンスキー，ウラジスラフ
サブチュク，ニコライ
ヴァシリエヴィチ イヴァチチェンコ，アレクサンドル
クヴァト，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bala Therapeutics Inc
Original Assignee
Bala Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bala Therapeutics Inc filed Critical Bala Therapeutics Inc
Publication of JP2024545184A publication Critical patent/JP2024545184A/ja
Priority to JP2025137487A priority Critical patent/JP2025170331A/ja
Publication of JP2024545184A5 publication Critical patent/JP2024545184A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024534648A 2021-12-09 2022-12-09 メニン－ｍｌｌ相互作用の阻害剤 Pending JP2024545184A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025137487A JP2025170331A (ja) 2021-12-09 2025-08-21 メニン－ｍｌｌ相互作用の阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163287716P 2021-12-09 2021-12-09
US63/287,716 2021-12-09
US202263306399P 2022-02-03 2022-02-03
US63/306,399 2022-02-03
US202263397322P 2022-08-11 2022-08-11
US63/397,322 2022-08-11
PCT/US2022/052404 WO2023107696A2 (en) 2021-12-09 2022-12-09 Inhibitors of menin-mll interaction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025137487A Division JP2025170331A (ja) 2021-12-09 2025-08-21 メニン－ｍｌｌ相互作用の阻害剤

Publications (2)

Publication Number Publication Date
JP2024545184A true JP2024545184A (ja) 2024-12-05
JP2024545184A5 JP2024545184A5 (https=) 2025-08-29

Family

ID=86731242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024534648A Pending JP2024545184A (ja) 2021-12-09 2022-12-09 メニン－ｍｌｌ相互作用の阻害剤
JP2025137487A Pending JP2025170331A (ja) 2021-12-09 2025-08-21 メニン－ｍｌｌ相互作用の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025137487A Pending JP2025170331A (ja) 2021-12-09 2025-08-21 メニン－ｍｌｌ相互作用の阻害剤

Country Status (10)

Country Link
US (2) US20250163061A1 (https=)
EP (1) EP4444300A4 (https=)
JP (2) JP2024545184A (https=)
KR (2) KR20250135350A (https=)
AU (2) AU2022405438A1 (https=)
CA (1) CA3240074A1 (https=)
JO (1) JOP20240130A1 (https=)
MX (2) MX2024007069A (https=)
TW (2) TW202529770A (https=)
WO (1) WO2023107696A2 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
JP2018538330A (ja) * 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
US20200216471A1 (en) * 2017-09-20 2020-07-09 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
JP2018538330A (ja) * 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
US20200216471A1 (en) * 2017-09-20 2020-07-09 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use

Also Published As

Publication number Publication date
JP2025170331A (ja) 2025-11-18
KR20240117133A (ko) 2024-07-31
US20260022120A1 (en) 2026-01-22
WO2023107696A2 (en) 2023-06-15
MX2024007069A (es) 2024-08-22
EP4444300A4 (en) 2026-03-18
AU2025230651A1 (en) 2025-09-25
JOP20240130A1 (ar) 2024-06-10
TW202529770A (zh) 2025-08-01
MX2025012108A (es) 2025-11-03
US20250163061A1 (en) 2025-05-22
TW202337435A (zh) 2023-10-01
CA3240074A1 (en) 2023-06-15
EP4444300A2 (en) 2024-10-16
KR20250135350A (ko) 2025-09-12
WO2023107696A3 (en) 2023-07-27
AU2022405438A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
AU2022200741B2 (en) Aminothiazole compounds as c-Kit inhibitors
CA2976741C (en) 1-cyano-pyrrolidine compounds as usp30 inhibitors
AU2019283921A1 (en) Indole carboxamide compounds useful as kinase inhibitors
CN110291081A (zh) 作为c-kit抑制剂的苯并咪唑化合物
WO2015165341A1 (zh) 作为rho激酶抑制剂的异喹啉磺酰衍生物
JP2026504821A (ja) Ｎｌｒｐ３阻害剤としての有機化合物
AU2023249498B2 (en) Lrrk2 inhibitors
CN110099906A (zh) 作为激酶抑制剂的酰胺化合物
JP2025513549A (ja) 癌治療におけるｅｇｆｒ阻害剤
JP2024545184A (ja) メニン－ｍｌｌ相互作用の阻害剤
TW202517653A (zh) 治療自體免疫疾病之大環
WO2024107658A2 (en) Inhibitors of tyk2
JP2025507758A (ja) Ｍａｌｔ１のｐｒｏｔａｃｓ
US20250115577A1 (en) BCL-2 Inhibitors
JP2025517026A (ja) Ｐｔｐｎ２阻害剤
CN118647378A (zh) 梅嫩蛋白与mll相互作用的抑制剂
JP2024545511A (ja) メニン－ｍｌｌ相互作用の阻害剤
WO2025175264A1 (en) Inhibitors of cdk2
WO2026019442A1 (en) Compounds having (3-nitrophenyl)acetamide as bcl-2 inhibitors
EP4416151A1 (en) Chimeric compounds useful in treating diseases
WO2025251058A1 (en) Egfr inhibitors in cancer treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260317